Australia Oligonucleotide Therapeutics Market Size & Outlook
Related Markets
Australia oligonucleotide therapeutics market highlights
- The Australia oligonucleotide therapeutics market generated a revenue of USD 121.0 million in 2025 and is expected to reach USD 705.2 million by 2033.
- The Australia market is expected to grow at a CAGR of 24.7% from 2026 to 2033.
- In terms of segment, antisense oligonucleotides (asos) was the largest revenue generating oligonucleotide class in 2025.
- MicroRNA (miRNA) is the most lucrative oligonucleotide class segment registering the fastest growth during the forecast period.
Oligonucleotide therapeutics market data book summary
| Market revenue in 2025 | USD 121.0 million |
| Market revenue in 2033 | USD 705.2 million |
| Growth rate | 24.7% (CAGR from 2026 to 2033) |
| Largest segment | Antisense oligonucleotides (asos) |
| Fastest growing segment | MicroRNA (miRNA) |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Antisense Oligonucleotides (ASOs), Small Interfering RNA (siRNA), Aptamers, MicroRNA (miRNA), CpG Oligonucleotides, Other Oligonucleotide Therapeutics |
Other key industry trends
- In terms of revenue, Australia accounted for 1.7% of the global oligonucleotide therapeutics market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, Japan oligonucleotide therapeutics market is projected to lead the regional market in terms of revenue in 2033.
- Japan is the fastest growing regional market in Asia Pacific and is projected to reach USD 2,428.9 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Oligonucleotide Therapeutics Market Scope
Oligonucleotide Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Wave Life Sciences | View profile | 251-500 | Boston, Massachusetts, United States, North America | http://wavelifesciences.com |
| Sarepta Therapeutics Inc | View profile | 1314 | 215 First Street, Suite 415, Cambridge, MA, United States, 02142 | https://www.sarepta.com |
| Silence Therapeutics PLC | View profile | 109 | 72 Hammersmith Road, London, United Kingdom, W14 8TH | https://www.silence-therapeutics.com |
| Arrowhead Pharmaceuticals Inc | View profile | 525 | 177 E. Colorado Boulevard, Suite 700, Pasadena, CA, United States, 91105 | https://www.arrowheadpharma.com |
| Alnylam Pharmaceuticals Inc | View profile | 2100 | 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, United States, 02142 | https://www.alnylam.com |
| Ionis Pharmaceuticals Inc | View profile | 927 | 2855 Gazelle Court, Carlsbad, CA, United States, 92010 | https://www.ionispharma.com |
| Biogen Inc | View profile | 7570 | 225 Binney Street, Cambridge, MA, United States, 02142 | https://www.biogen.com |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | http://www.roche.com |
| Nitto Denko Corp | View profile | 28193 | 4-20, Ofuka-Cho, 33rd Floor, Grand Front Osaka, Kita-Ku, Osaka, Japan, 530-0011 | http://www.nitto.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
Australia oligonucleotide therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to oligonucleotide therapeutics market will help companies and investors design strategic landscapes.
Antisense oligonucleotides (asos) was the largest segment with a revenue share of 56.69% in 2025. Horizon Databook has segmented the Australia oligonucleotide therapeutics market based on antisense oligonucleotides (asos), small interfering rna (sirna), aptamers, microrna (mirna), cpg oligonucleotides, other oligonucleotide therapeutics covering the revenue growth of each sub-segment from 2021 to 2033.
Reasons to subscribe to Australia oligonucleotide therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia oligonucleotide therapeutics market databook
-
Our clientele includes a mix of oligonucleotide therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia oligonucleotide therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Australia oligonucleotide therapeutics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Australia oligonucleotide therapeutics market size, by oligonucleotide class, 2021-2033 (US$M)
Australia Oligonucleotide Therapeutics Market Outlook Share, 2025 & 2033 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
